{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:19:40Z","timestamp":1793229580505,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.msard.2023.104735","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T20:34:50Z","timestamp":1682454890000},"page":"104735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-5761","authenticated-orcid":false,"given":"Sofie","family":"Aerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Severijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Wijmeersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.msard.2023.104735_bib0001","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2023.104735_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102945","article-title":"A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis","volume":"52","author":"Bose","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2023.104735_bib0003","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/brain\/awz156","article-title":"Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis","volume":"142","author":"Brownlee","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104735_bib0004","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104735_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104735_bib0006","unstructured":"EMA, 2022. Mavenclad (cladribine) \u2013 risk of serious liver injury and new recommendations about liver function monitoring. . https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/mavenclad-cladribine-risk-serious-liver-injury-new-recommendations-about-liver-function-monitoring. (Accessed 23\/01\/2023."},{"key":"10.1016\/j.msard.2023.104735_bib0007","unstructured":"EMA, 2022. Mavenclad : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mavenclad. (Accessed 07\/10\/2022."},{"issue":"5","key":"10.1016\/j.msard.2023.104735_bib0008","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2023.104735_bib0009","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104735_bib0010","article-title":"Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study","author":"Giovannoni","year":"2021","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2023.104735_bib0011","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2023.104735_bib0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104735_bib0013","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104735_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419887596","article-title":"Therapy with cladribine is efficient and safe in patients previously treated with natalizumab","volume":"12","author":"M\u00f6hn","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.msard.2023.104735_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS: the ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.msard.2023.104735_bib0016","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/acn3.51206","article-title":"Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS","volume":"7","author":"Moser","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2023.104735_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103812","article-title":"Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis","volume":"62","author":"Nygaard","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104735_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13","author":"Patti","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.104735_bib0019","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2023.104735_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104735_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103755","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","volume":"61","author":"Rauma","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.104735_bib0022","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000990","article-title":"Skin reactions in patients with multiple sclerosis receiving cladribine treatment","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104735_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104735_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419854986","article-title":"Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers","volume":"12","author":"Stuve","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.104735_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104735_bib0026","unstructured":"US Department of Health and Human Services, 2022. Common Terminology Criteria for Adverse Events (CTCAE). Protocol Development. CTEP. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. (Accessed 07\/11\/2022."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:00Z","timestamp":1761901620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"alternative-id":["S2211034823002390"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104735","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104735"}}